| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A-beta oligomers and brain pathology: a difficult marriage
|
Giacobini, Ezio
|
|
2016
|
39 |
S1 |
p. S3-
1 p.
|
artikel
|
| 2 |
A clinical trial investigating the effects of fortasyn connect (souvenaid) in prodromal Alzheimer’s disease: results of the LipiDiDiet study
|
Soininen, Hilkka
|
|
2016
|
39 |
S1 |
p. S23-
1 p.
|
artikel
|
| 3 |
Acute care Alzheimer units
|
Zekry, Dina
|
|
2016
|
39 |
S1 |
p. S16-
1 p.
|
artikel
|
| 4 |
Alpha-synuclein aggregation and synaptic pathology in Parkinson’s disease and Dementia with Lewy Bodies
|
Stefanis, Leonidas
|
|
2016
|
39 |
S1 |
p. S4-
1 p.
|
artikel
|
| 5 |
Alzheimer disease and sleep
|
Elble, Rodger
|
|
2016
|
39 |
S1 |
p. S3-
1 p.
|
artikel
|
| 6 |
Amyloid imaging: what can it tell us?
|
Villemagne, Victor
|
|
2016
|
39 |
S1 |
p. S12-
1 p.
|
artikel
|
| 7 |
Amyloid pet imaging: prime 1b study
|
Sevigny, Jeff
|
|
2016
|
39 |
S1 |
p. S25-
1 p.
|
artikel
|
| 8 |
Amyloid reducing therapies: do they still have a future?
|
Korczyn, Amos
|
|
2016
|
39 |
S1 |
p. S5-
1 p.
|
artikel
|
| 9 |
An overview of RVT-101, a neurotransmitter-targeted therapy in clinical trials for dementia: effects on cognition and activities of daily living and future development plans in Alzheimer’s disease and dementia with Lewy bodies
|
Ramaswamy, Geetha
|
|
2016
|
39 |
S1 |
p. S21-
1 p.
|
artikel
|
| 10 |
Antihypertensive regimen intensity and incident dementia: a longitudinal, population-based study
|
Tan, Edwin
|
|
2016
|
39 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 11 |
Anti-tau therapy in the clinic: what will it look like?
|
Gauthier, Serge
|
|
2016
|
39 |
S1 |
p. S1-
1 p.
|
artikel
|
| 12 |
Anti-Tau therapy - is it the answer?
|
Mandelkow, Eva-Maria
|
|
2016
|
39 |
S1 |
p. S25-
1 p.
|
artikel
|
| 13 |
APOE polymorphism and cortical plasticity are independently associated with cognitive decline in Alzheimer’s disease
|
Di Lorenzo, Francesco
|
|
2016
|
39 |
S1 |
p. S30-S31
2 p.
|
artikel
|
| 14 |
APOE4: The most prevalent yet understudied risk factor for Alzheimer’s disease
|
Michaelson, Daniel
|
|
2016
|
39 |
S1 |
p. S24-
1 p.
|
artikel
|
| 15 |
Are subjects with preclinical AD the best population for the study of disease modifiers treatment?
|
Dubois, Bruno
|
|
2016
|
39 |
S1 |
p. S28-
1 p.
|
artikel
|
| 16 |
assessing incidental memory in patients with amnestic mild cognitive impairment (AMCI) and mild Alzheimers disease (AD): the role of hippocampal atrophy
|
Kontaxopoulou, Dionysia
|
|
2016
|
39 |
S1 |
p. S30-
1 p.
|
artikel
|
| 17 |
Assessment of altered cerebral copper metabolism in transgenic mouse model of Alzheimer’s disease using 64CuCl2-PET/CT
|
Peng, Fangyu
|
|
2016
|
39 |
S1 |
p. S16-S17
2 p.
|
artikel
|
| 18 |
A unique target for a comprehensive therapy of Alzheimer’s disease: concomitant activation of SIGMA1/M1 muscarinic receptors
|
Fisher, Abraham
|
|
2016
|
39 |
S1 |
p. S5-
1 p.
|
artikel
|
| 19 |
Author Index
|
|
|
2016
|
39 |
S1 |
p. S32-S34
3 p.
|
artikel
|
| 20 |
Baseline CSF Aβ, Aβ/T-TAU and Aβ/P-tau distributions to classify pharmacog MCI patients
|
Marizzoni, Moira
|
|
2016
|
39 |
S1 |
p. S30-
1 p.
|
artikel
|
| 21 |
Biomarkers: selecting subjects for prevention and trials
|
Hugon, Jacques
|
|
2016
|
39 |
S1 |
p. S7-
1 p.
|
artikel
|
| 22 |
Building Pace and Scale in the Fight Against Alzheimer’s: The Road to 2025 and Beyond
|
Vradenburg, George
|
|
2016
|
39 |
S1 |
p. S31-
1 p.
|
artikel
|
| 23 |
Can MRI measure drug efficacy? Brain MRI studies in IMI PharmaCog WP5 / European ADNI
|
Frisoni, Giovanni
|
|
2016
|
39 |
S1 |
p. S23-
1 p.
|
artikel
|
| 24 |
Caring for complex older patients: the influence of cognitive status
|
Bernabei, Roberto
|
|
2016
|
39 |
S1 |
p. S23-
1 p.
|
artikel
|
| 25 |
Cell to cell propagation of tauopathy: a new therapeutic target
|
Duff, Karen
|
|
2016
|
39 |
S1 |
p. S10-
1 p.
|
artikel
|
| 26 |
Cerebrospinal fluid Aβ42/Aβ40 and Aβ42/Aβ38 as biomarkers of Alzheimer’s disease
|
Janelidze, Shorena
|
|
2016
|
39 |
S1 |
p. S28-
1 p.
|
artikel
|
| 27 |
Comparison of Early-Phase (S)-[18F]THK5117 and [11C]PIB PET imaging to assess brain perfusion in Alzheimer’s disease
|
Rodriguez-Vieitez, Elena
|
|
2016
|
39 |
S1 |
p. S21-
1 p.
|
artikel
|
| 28 |
Conformational heterogeneity of tau lesions captured by PET and its clinical significance
|
Higuchi, Makato
|
|
2016
|
39 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 29 |
Contents
|
|
|
2016
|
39 |
S1 |
p. iv-x
nvt p.
|
artikel
|
| 30 |
Coordinate-based meta-analysis of resting fMRI studies for the identification of potential targets for brain stimulation in AD and bvFTD
|
Pievani, Michela
|
|
2016
|
39 |
S1 |
p. S8-
1 p.
|
artikel
|
| 31 |
CSF analysis detect cerebral β-amyloid accumulation earlier than amyloid PET
|
Hansson, Oskar
|
|
2016
|
39 |
S1 |
p. S7-
1 p.
|
artikel
|
| 32 |
CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD
|
Nikolcheva, Tania
|
|
2016
|
39 |
S1 |
p. S28-S29
2 p.
|
artikel
|
| 33 |
Decreased ratio between β-amyloid 42 (Aβ42) and Aβ40 in cerebral spinal fluid is a better predictor of structural brain changes than Aβ42 alone in cognitively normal elderly people
|
Lindberg, Olof
|
|
2016
|
39 |
S1 |
p. S17-
1 p.
|
artikel
|
| 34 |
Depression, apathy and Alzheimer’s disease: new perspectives
|
Robert, Philippe
|
|
2016
|
39 |
S1 |
p. S29-S30
2 p.
|
artikel
|
| 35 |
Design of the phase II clinical study of the tau vaccine AADvac1 in patients with mild Alzheimer’s disease
|
Ondrus, Matej
|
|
2016
|
39 |
S1 |
p. S26-
1 p.
|
artikel
|
| 36 |
Dian study: first results
|
Morris, John
|
|
2016
|
39 |
S1 |
p. S11-
1 p.
|
artikel
|
| 37 |
Disentangling the interaction between amyloid and tau: where are we now?
|
Hardy, John
|
|
2016
|
39 |
S1 |
p. S21-
1 p.
|
artikel
|
| 38 |
Down syndrome dementia and Alzheimer disease: common pathology, common therapeutic targets
|
Wisniewski, Thomas
|
|
2016
|
39 |
S1 |
p. S24-
1 p.
|
artikel
|
| 39 |
Driving errors, accidents and their predictors in patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD)
|
Papageorgiou, Sokratis
|
|
2016
|
39 |
S1 |
p. S15-
1 p.
|
artikel
|
| 40 |
Dystrophic neurites are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation: the potential role of Aβ oligomers
|
Vassar, Robert J.
|
|
2016
|
39 |
S1 |
p. S25-
1 p.
|
artikel
|
| 41 |
Editorial Advisory Board
|
|
|
2016
|
39 |
S1 |
p. IFC-
1 p.
|
artikel
|
| 42 |
Education and cognitive reserve: more resistance or less disease?
|
Herrmann, Francois
|
|
2016
|
39 |
S1 |
p. S18-
1 p.
|
artikel
|
| 43 |
EEG markers of subtle cognitive deterioration in healthy elderly individuals
|
Giannakopoulos, Panteleimon
|
|
2016
|
39 |
S1 |
p. S1-
1 p.
|
artikel
|
| 44 |
Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate ad: combined sub-group analyses from two Phase 3 trials
|
Tolar, Martin
|
|
2016
|
39 |
S1 |
p. S22-
1 p.
|
artikel
|
| 45 |
Elucidation of the key molecular mechanisms associated with early Aβ peptide aggregation allows for an antibody enabled targeting of specific epitopes in Aβ oligomer
|
Schmid, Adrien
|
|
2016
|
39 |
S1 |
p. S28-
1 p.
|
artikel
|
| 46 |
Familial and idiopathic Alzheimer are not the same disease
|
Savioz, Armand
|
|
2016
|
39 |
S1 |
p. S3-S4
2 p.
|
artikel
|
| 47 |
Frontotemporal dementia: keeping up with change
|
Kövari, Enikö
|
|
2016
|
39 |
S1 |
p. S20-
1 p.
|
artikel
|
| 48 |
Gene-environment interaction in AD: we are just at the beginning
|
Fratiglioni, Laura
|
|
2016
|
39 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 49 |
Genetic evidence for microglia-associated pathways as therapeutic targets for Alzheimer's disease
|
Villegas-Llerena, Claudio
|
|
2016
|
39 |
S1 |
p. S6-
1 p.
|
artikel
|
| 50 |
Human-derived monoclonal antibodies for Alzheimer’s disease and related proteinopathies
|
Grimm, Jan
|
|
2016
|
39 |
S1 |
p. S25-
1 p.
|
artikel
|
| 51 |
Human gut microbiome is related to neurodegenerative diseases
|
Scheperjans, Filip
|
|
2016
|
39 |
S1 |
p. S10-
1 p.
|
artikel
|
| 52 |
Idalopirdine, a 5-HT6 antagonist in Phase III development as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: the observed case analyses of the Phase II study
|
Cummings, Jeffrey
|
|
2016
|
39 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 53 |
Idalopirdine, a 5-HT6 receptor antagonist in development for the treatment of mild-moderate Alzheimer’s disease: the scientific rationale
|
de Jong, Inge
|
|
2016
|
39 |
S1 |
p. S12-
1 p.
|
artikel
|
| 54 |
Imaging neuroinflammation in Alzheimer’s and other dementias: recent advances and future directions
|
Brooks, David
|
|
2016
|
39 |
S1 |
p. S9-
1 p.
|
artikel
|
| 55 |
Improved concordance between [11C]PIB PET and CSF Aβ42 using Aβ42/Aβ40: findings from a multicentre European memory clinic population
|
Leuzy, Antoine
|
|
2016
|
39 |
S1 |
p. S18-
1 p.
|
artikel
|
| 56 |
Inflammation and its resolution – studies in Alzheimer’s disease
|
Schultzberg, Marianne
|
|
2016
|
39 |
S1 |
p. S17-
1 p.
|
artikel
|
| 57 |
Intrabodies targeting AMYLOID-β oligomers in the endoplasmic reticulum: preclinical evidences for new twist in immunotherapy
|
Meli, Giovanni
|
|
2016
|
39 |
S1 |
p. S22-
1 p.
|
artikel
|
| 58 |
Intranasal but not intraparenchimal delivery of painless nerve growth factor rescues memory deficits in a mouse model of Alzheimer’s disease by targeting glial cells and reducing amyloid deposition through enhancement of neuronal SDF-1α
|
Capsoni, Simona
|
|
2016
|
39 |
S1 |
p. S19-S20
2 p.
|
artikel
|
| 59 |
In vitro characterization of fibrillar amyloid, tau deposits, and activated astrocytes in Arctic APP and sporadic Alzheimer's disease brain using, 3H-PIB and 3H-THK5117 and 3H-Deprenyl in comparison to immunostaining
|
Lemoine, Laetitia
|
|
2016
|
39 |
S1 |
p. S15-
1 p.
|
artikel
|
| 60 |
Is dementia prevalence rising or declining?
|
Albanese, Emiliano
|
|
2016
|
39 |
S1 |
p. S27-
1 p.
|
artikel
|
| 61 |
Landscape of antibody immunotherapy for Alzheimer’s disease
|
Hock, Christoph
|
|
2016
|
39 |
S1 |
p. S25-S26
2 p.
|
artikel
|
| 62 |
Lifestyle intervention to prevent cognitive impairment
|
Kivipelto, Miia
|
|
2016
|
39 |
S1 |
p. S18-
1 p.
|
artikel
|
| 63 |
Longitudinal studies of regional tau deposition in brain by PET
|
Nordberg, Agneta
|
|
2016
|
39 |
S1 |
p. S19-
1 p.
|
artikel
|
| 64 |
Lower blood and brain nutrient status in AD: results from a meta-analysis
|
Wilde, Martijn de
|
|
2016
|
39 |
S1 |
p. S20-
1 p.
|
artikel
|
| 65 |
Masitinib for the treatment of Alzheimer’s disease: clinical and preclinical data
|
Hermine, Olivier
|
|
2016
|
39 |
S1 |
p. S4-S5
2 p.
|
artikel
|
| 66 |
Maturity of Aβ42, tau, and phospho-tau in the cerebrospinal fluid as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
|
Mattsson, Niklas
|
|
2016
|
39 |
S1 |
p. S13-
1 p.
|
artikel
|
| 67 |
Mechanisms of neuronal death in familial Alzheimer disease and therapeutic implications
|
Robakis, Nikolaos
|
|
2016
|
39 |
S1 |
p. S14-
1 p.
|
artikel
|
| 68 |
Memory clinic, diagnosis and beyond
|
Vadikolias, Konstantinos
|
|
2016
|
39 |
S1 |
p. S14-
1 p.
|
artikel
|
| 69 |
Metal dysfunction and Alzheimer's disease
|
Squitti, Rosanna
|
|
2016
|
39 |
S1 |
p. S7-
1 p.
|
artikel
|
| 70 |
Microglia in neurodegeneration: a (re)introduction
|
Ransohoff, Richard
|
|
2016
|
39 |
S1 |
p. S21-
1 p.
|
artikel
|
| 71 |
Microinfarcts and microbleeds in brain aging
|
Gold, Gabriel
|
|
2016
|
39 |
S1 |
p. S14-
1 p.
|
artikel
|
| 72 |
Molecular PET imaging as correlates to drug response
|
Nordberg, Agneta
|
|
2016
|
39 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 73 |
Multifunctional effect of human serum albumin reduces Alzheimer disease related pathologies in the 3xTg mice model
|
Solomon, Beka
|
|
2016
|
39 |
S1 |
p. S2-
1 p.
|
artikel
|
| 74 |
Multi-nutrient intervention in prodromal Alzheimer’s disease: rationale based on results from the lipididiet programme
|
Hartmann, Tobias
|
|
2016
|
39 |
S1 |
p. S26-
1 p.
|
artikel
|
| 75 |
National Alzheimer plans what is actually happening on the ground: practical lessons from Canada
|
Bergman, Howard
|
|
2016
|
39 |
S1 |
p. S1-
1 p.
|
artikel
|
| 76 |
New ligands of choline acetyltransferase as therapeutics and in vivo functional biomarkers in Alzheimer’s disease
|
Darreh-Shori, Taher
|
|
2016
|
39 |
S1 |
p. S29-
1 p.
|
artikel
|
| 77 |
Non pharmacological interventions for Alzheimer's disease
|
Tsolaki, Magda
|
|
2016
|
39 |
S1 |
p. S27-
1 p.
|
artikel
|
| 78 |
Oligomer antibodies for Alzheimer’s research, diagnostics and therapeutics
|
Klein, William
|
|
2016
|
39 |
S1 |
p. S5-
1 p.
|
artikel
|
| 79 |
Pathways to Alzheimer's disease and other neurodegenerative diseases
|
Hardy, John
|
|
2016
|
39 |
S1 |
p. S13-
1 p.
|
artikel
|
| 80 |
Phagocytic characterization and therapeutic efficacy of an anti-PyroGlutamate-3 Aβ IgG2a antibody in aged APP/PS1dE9 mice
|
Lemere, Cynthia
|
|
2016
|
39 |
S1 |
p. S12-S13
2 p.
|
artikel
|
| 81 |
Pharmaceutical implications of the paradigm shift in understanding and treatment of late life neurodegenerative disorders
|
Wischik, Claude
|
|
2016
|
39 |
S1 |
p. S10-
1 p.
|
artikel
|
| 82 |
Plasma levels of lipoprotein (a) and apolipoprotein A1 in patients with probable Alzheimer’s disease
|
Politis, Antonios
|
|
2016
|
39 |
S1 |
p. S20-
1 p.
|
artikel
|
| 83 |
Prevention of propagation of tau pathology with antibodies to its amino terminal domain
|
Iqbal, Khalid
|
|
2016
|
39 |
S1 |
p. S4-
1 p.
|
artikel
|
| 84 |
Proteomic links to CJD viral particles highlight common pathways for neurodegenerative diseases
|
Manuelidis, Laura
|
|
2016
|
39 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 85 |
PSP and small vessel disease: more than occasional co-occurence?
|
Sieben, Anne
|
|
2016
|
39 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 86 |
Relation of CSF markers to drug effects in Alzheimer’s disease trials
|
Blennow, Kaj
|
|
2016
|
39 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 87 |
Relationships between tau deposition, cognition, and β-amyloid
|
Jagust, William
|
|
2016
|
39 |
S1 |
p. S2-
1 p.
|
artikel
|
| 88 |
Secondary prevention trials in preclinical Alzheimer's disease
|
Sperling, Reisa
|
|
2016
|
39 |
S1 |
p. S16-
1 p.
|
artikel
|
| 89 |
Short-term response to cholinesterase inhibitors in Alzheimer’s disease delays time to nursing home placement
|
Wattmo, Carina
|
|
2016
|
39 |
S1 |
p. S2-
1 p.
|
artikel
|
| 90 |
Simultaneous quantitative susceptibility mapping-MRI and 18F-Flutametamol-PET indicate functional impact of cerebral iron and Amyloid-β plaque burden in cognitively normal super-agers
|
van Bergen, Jiri
|
|
2016
|
39 |
S1 |
p. S9-
1 p.
|
artikel
|
| 91 |
Specific alterations of tau phosphorylation and neuronal signaling induced by the amyloid-β oligomer Aβ*56
|
Lesne, Sylvain
|
|
2016
|
39 |
S1 |
p. S27-
1 p.
|
artikel
|
| 92 |
Stages of CNS inflammation in Alzheimer's disease
|
Eikelenboom, Piet
|
|
2016
|
39 |
S1 |
p. S4-
1 p.
|
artikel
|
| 93 |
Stem cells for Alzheimer’s disease: transition to clinical trials
|
Bolmont, Tristan
|
|
2016
|
39 |
S1 |
p. S13-
1 p.
|
artikel
|
| 94 |
Structural constraints for the spreading of tau pathology
|
Mandelkow, Eckhard
|
|
2016
|
39 |
S1 |
p. S24-
1 p.
|
artikel
|
| 95 |
Supplement Title Page
|
|
|
2016
|
39 |
S1 |
p. iii-
1 p.
|
artikel
|
| 96 |
Tau and Alzheimer pathobiology
|
Hyman, Bradley
|
|
2016
|
39 |
S1 |
p. S16-
1 p.
|
artikel
|
| 97 |
Tau imaging: what can it tell us?
|
Devous, Michael
|
|
2016
|
39 |
S1 |
p. S11-
1 p.
|
artikel
|
| 98 |
Tau pet imaging in neurodegenerative tauopathies – a multimodal paradigm
|
Chiotis, Konstantinos
|
|
2016
|
39 |
S1 |
p. S29-
1 p.
|
artikel
|
| 99 |
Tau PET in aging and AD
|
Johnson, Keith
|
|
2016
|
39 |
S1 |
p. S19-
1 p.
|
artikel
|
| 100 |
Tau-specific D-enantiomeric peptides for therapeutic applications in Alzheimer’s disease
|
Funke, Susanne
|
|
2016
|
39 |
S1 |
p. S13-
1 p.
|
artikel
|
| 101 |
The Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) trial
|
Langbaum, Jessica
|
|
2016
|
39 |
S1 |
p. S8-S9
2 p.
|
artikel
|
| 102 |
The brain cholinergic system in neurodegenerative diseases
|
Pepeu, Giancarlo
|
|
2016
|
39 |
S1 |
p. S3-
1 p.
|
artikel
|
| 103 |
The early and late inflammatory processes in the Alzheimer’s pathology
|
Cuello, A. Claudio
|
|
2016
|
39 |
S1 |
p. S12-
1 p.
|
artikel
|
| 104 |
The effect of Souvenaid on brain phospholipid metabolism in patients with mild Alzheimer’s disease: results of a randomised controlled 31P-Magnetic Resonance Spectroscopy study
|
Rijpma, Anne
|
|
2016
|
39 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 105 |
The European Medicines Agency’s strategies to tackle the challenges of AD drug development
|
Mantua, Valentina
|
|
2016
|
39 |
S1 |
p. S6-
1 p.
|
artikel
|
| 106 |
The human brain: the path from normal aging to Alzheimer’s disease
|
Bouras, Constantin
|
|
2016
|
39 |
S1 |
p. S11-
1 p.
|
artikel
|
| 107 |
The immunology of the first tau vaccine for Alzheimer’s disease therapy: new findings and challenges
|
Žilka, Norbert
|
|
2016
|
39 |
S1 |
p. S31-
1 p.
|
artikel
|
| 108 |
The incremental diagnostic value of 18F-Florbetapir imaging in naturalistic patients with cognitive impairment: final results from the india-FBP study
|
Boccardi, Marina
|
|
2016
|
39 |
S1 |
p. S27-
1 p.
|
artikel
|
| 109 |
The ins and outs of tau propagation
|
Buee, Luc
|
|
2016
|
39 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 110 |
The pyroglutamate modification of toxic Aβ resulted new therapeutic aproaches: inhibitors of glutaminyl cyclase and highly specific antibodies – a status report
|
Demuth, Hans-Ulrich
|
|
2016
|
39 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 111 |
Time to forget mice? Using human cells for drug testing?
|
Windisch, Manfred
|
|
2016
|
39 |
S1 |
p. S9-
1 p.
|
artikel
|
| 112 |
Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous ad patients: efficacy and safety analyses from two Phase 3 trials
|
Abushakra, Susan
|
|
2016
|
39 |
S1 |
p. S22-
1 p.
|
artikel
|
| 113 |
Transmission of misfolded proteins in neurodegenerative disorders: a common mechanism of disease progression
|
Lee, Virginia
|
|
2016
|
39 |
S1 |
p. S8-
1 p.
|
artikel
|
| 114 |
Transmission of neuronal and glial tau pathology: new models for developing disease modifying therapy for Alzheimer's and related tauopathies
|
Trojanowski, John
|
|
2016
|
39 |
S1 |
p. S6-
1 p.
|
artikel
|
| 115 |
Trem2 deficiency is protective early but detrimental late in disease progression in an amyloid mouse model of Alzheimer's disease
|
Jay, Taylor
|
|
2016
|
39 |
S1 |
p. S17-
1 p.
|
artikel
|
| 116 |
Type 1 and Type 2 Aβ oligomers in the brain
|
Ashe, Karen
|
|
2016
|
39 |
S1 |
p. S26-
1 p.
|
artikel
|
| 117 |
Understanding site preferences with electronic Clinical Outcome Assessment (eCOA) technologies: a multinational survey
|
Lytle, Douglas
|
|
2016
|
39 |
S1 |
p. S11-
1 p.
|
artikel
|
| 118 |
What did the ancient Greek philosophers know about the relation between the mind and the brain
|
Papanicolaou, Andrew
|
|
2016
|
39 |
S1 |
p. S15-
1 p.
|
artikel
|
| 119 |
What will be the best treatment for Alzheimer disease?
|
Winblad, Bengt
|
|
2016
|
39 |
S1 |
p. S19-
1 p.
|
artikel
|
Tijdschrift beschrijving